microalbuminuria screening

microalbuminuria screening

The evaluation of urine for minute amounts of albumin, which may be an early indicator of diabetic nephropathy, requiring aggressive management. MS should begin five years after onset of diabetes and be measured annually.
References in periodicals archive ?
Incerti J et al in the assessment of different tests for microalbuminuria screening in diabetic patients concluded 100% sensitivity and 73.0% specificity at cut off value of 15.7 mg/g for urine ACR12.
The cost-effectiveness of microalbuminuria screening. Am J Kidney Dis.
Several studies have demonstrated cost-effectiveness of microalbuminuria screening in high-risk populations leading optimization of patients' care as well as future implementation of CKD screening programs [8, 9, 13].
(8) In addition, the urine albumin concentration in fasting morning urine samples is suggested for microalbuminuria screening by the European Diabetes Policy Group.
Does microalbuminuria screening in diabetes prevent complications?
The use of semiquantitative urine test strip (Micral) for microalbuminuria screening in patients with diabetes mellitus.
No studies have examined the role of microalbuminuria screening after angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) have been instituted for other indications.
* CONCLUSIONS Physician use of microalbuminuria screening does not follow established guidelines.
* Annual microalbuminuria screening is recommended by the panels of several organizations.
* The microalbuminuria screening rate for patients who did not have proteinuria was no different from those with proteinuria or those already taking an ACEI or ARB.
Although there are no controlled trials that show microalbuminuria screening as effective at reducing proteinuria, expert panels of the American Diabetes Association[8] and National Kidney Foundation[9] have recommended that patients with type 2 diabetes receive annual screening for microalbuminuria, and if it is detected on 2 of 3 occasions, these patients should be placed on an ACEI or an angiotensin receptor blocker (ARB) for renal protection.